

Morgan Stanley

Key Information Document

Purpose

This document provides you with key information about this product. It is not marketing material. The information is required by the Packaged Retail and Insurance-Based Investment Products Regulation (“PRIIPs”) to help you understand the key features, risks, costs and potential gains and losses of this product and to help you compare it with other products covered by PRIIPs.

Product

Product name	Barrier Worst-of Reverse Convertible Note Linked to a Basket of Indices
Product identifier	ISIN: XS3211881688
PRIIP manufacturer	Morgan Stanley & Co. International plc (https://sp.morganstanley.com/EU/). The product issuer is Morgan Stanley B.V. with a guarantee by Morgan Stanley.
Telephone number	+44-20-7677-6140
Date and time of production	27 November 2025 17:17 London local time

You are about to purchase a product that is not simple and may be difficult to understand.

1. What is this product?

Type

English law governed equity-linked notes / Return depends on the performance of the underlyings / No capital protection against market risk

Objectives

(Terms that appear in **bold** in this section are described in more detail in the table(s) below.)

The product is designed to provide a return in the form of (1) regular fixed interest payments and (2) a cash payment on the **maturity date**. The amount of this payment will depend on the performance of the **underlyings**. The product has a fixed term and will terminate on the **maturity date**. If, at maturity, the **final reference level of the worst performing underlying** has fallen below its **barrier level**, the product may return less than the **product notional amount** or even zero.

Interest: On each **interest payment date** you will receive an interest payment of GBP 5.00. The interest payments are not linked to the performance of the **underlyings**. The relevant dates are shown in the table(s) below.

Interest payment dates
14 April 2026
12 May 2026
10 June 2026
13 July 2026
10 August 2026
11 September 2026
12 October 2026
10 November 2026
11 December 2026
13 January 2027
10 February 2027
12 March 2027
13 April 2027
12 May 2027
11 June 2027
12 July 2027
10 August 2027
13 September 2027
11 October 2027
10 November 2027
13 December 2027
13 January 2028
10 February 2028
13 March 2028
10 April 2028
12 May 2028
13 June 2028
11 July 2028
10 August 2028
12 September 2028
11 October 2028
10 November 2028
11 December 2028
11 January 2029
12 February 2029
13 March 2029
12 April 2029
14 May 2029
12 June 2029
11 July 2029
10 August 2029
11 September 2029
11 October 2029
12 November 2029
11 December 2029
11 January 2030
11 February 2030
13 March 2030
10 April 2030
14 May 2030
11 June 2030
11 July 2030
12 August 2030

	10 September 2030
	11 October 2030
	11 November 2030
	11 December 2030
	13 January 2031
	10 February 2031
	13 March 2031
	10 April 2031
	13 May 2031
	10 June 2031
	11 July 2031
	11 August 2031
	10 September 2031
	13 October 2031
	10 November 2031
	12 December 2031
	13 January 2032
	10 February 2032
	Maturity date

Termination on the maturity date: On the **maturity date** you will receive:

1. if the **final reference level** of the **worst performing underlying** is at or above its **barrier level**, a cash payment equal to GBP 1,000.00; or
2. if the **final reference level** of the **worst performing underlying** is below its **barrier level**, a cash payment directly linked to the performance of the **worst performing underlying**. The cash payment will equal (i) the **product notional amount** multiplied by (ii) (A) the **final reference level** of the **worst performing underlying** divided by (B) its **strike level**.

Under the product terms, certain dates specified above and below will be adjusted if the respective date is either not a business day or not a trading day (as applicable). Any adjustments may affect the return, if any, you receive.

The product terms also provide that if certain exceptional events occur (1) adjustments may be made to the product and/or (2) the issuer may terminate the product early. These events are specified in the product terms and principally relate to the **underlyings**, the product and the issuer. The return (if any) you receive on such early termination is likely to be different from the scenarios described above and may be less than the amount you invested.

When purchasing this product during its lifetime, the purchase price may include accrued interest on a pro rata basis.

You do not have any entitlement to a dividend from any of the **underlyings** and you have no right to any further entitlement resulting from any such **underlying** (e.g., voting rights).


Underlyings	FTSE 100 INDEX (Price return index) (UKX; ISIN: GB0001383545; Bloomberg: UKX Index) and S&P 500 INDEX (Price return index) (SPX; ISIN: US78378X1072; Bloomberg: SPX Index)	Strike level	100.00% of the initial reference level
Asset class	Equity	Barrier level	65.00% of the initial reference level
Product notional amount	GBP 1,000.00	Reference level	The closing level of an underlying as per the relevant reference source
Issue price	100.00% of the product notional amount	Reference sources	• UKX: FTSE • SPX: Standard & Poor's
Product currency	Pound Sterling (GBP)	Final reference level	The reference level on the final valuation date
Underlying currencies	• UKX: GBP • SPX: U.S. Dollar (USD)	Initial valuation date	27 February 2026
Subscription period	4 December 2025 (inclusive) to 27 February 2026 (inclusive)	Final valuation date	27 February 2032
Issue date	13 March 2026	Maturity date / term	12 March 2032
Initial reference level	The reference level on the initial valuation date	Worst performing underlying	The underlying with the worst performance between the initial reference level and the final reference level

Intended retail investor The product is intended to be offered to retail investors who fulfil all of the criteria below:

1. they have basic knowledge and/or experience of investing in similar products which provide a similar market exposure and have the ability to understand the product and its possible risks and rewards, either independently or through professional advice;
2. they seek income, expect the movement in the underlyings to perform in a way that generates a positive return. They have a long investment horizon;
3. they are able to bear a total loss of their initial investment, consistent with the redemption profile of the product at maturity (market risk);
4. they accept the risk that the issuer or guarantor could fail to pay or perform its obligations under the product irrespective of the redemption profile of the product (credit risk);
5. they are willing to accept a level of risk of 3 out of 7 to achieve potential returns, which reflects a medium-low risk (as shown in the summary risk indicator below which takes into account both market risk and credit risk).

2. What are the risks and what could I get in return?

Risk indicator



The summary risk indicator is a guide to the level of risk of this product compared to other products. It shows how likely it is that the product will lose money because of movements in the markets or because we are not able to pay you.

We have classified this product as 3 out of 7, which is a medium-low risk class. This rates the potential losses from future performance at a medium-low level, and poor market conditions are very unlikely to impact our capacity to pay you.

To the extent the currency of the country in which you purchase this product or your account currency differs from the product currency, please be aware of currency risk. You will receive payments in a different currency so the final return you will get depends on the exchange rate between the two currencies. This risk is not considered in the indicator shown above.

Inflation erodes the purchasing value of cash over time and this may result in the decline in real terms of any capital reimbursed or interest you may be paid under the investment.

This product does not include any protection from future market performance so you could lose some or all of your investment.

For detailed information about all risks relating to the product please refer to the risk sections of the prospectus and any supplements thereto as specified in the section "7. Other relevant information" below.

Main factors likely to affect future returns on the product

Your return on the product at the end of the recommended holding period will principally be affected by (1) the price at which you purchase the product, (2) the performance of the **underlyings** over the recommended holding period and of the exchange rate between the product currency and the underlying currencies and (3) the ability of the issuer and guarantor to make payments that become due on the product. The value of the product before the **maturity date** will also be affected by general economic and market conditions, the volatility of the **underlyings** (which is a measure of the extent of movement in the levels of the **underlyings**), interest rates, exchange rates, the correlation between the various **underlyings**, the remaining time to maturity and the ability of the issuer and guarantor to make payments.

What could affect my return positively?

- The product provides a return in the form of fixed rate interest payments and, as such, there are no factors that could positively affect your return.

Investment performance information

What could affect my return negatively?

- A decrease in the levels of the **underlyings**
- The occurrence of a barrier event
- The issuer's and the guarantor's inability to make payments on the product when they fall due

The factors listed above provide general guidance on how changes in the levels of the **underlyings** may affect your return if you purchase the product at inception and hold it to the end of the recommended holding period. If you purchase or sell the product after inception, your return on the product will also be affected by the purchase or sale price and the levels of the **underlyings** at the time of sale or, in the case of a purchase, at and following the time of purchase. The precise impact will depend on the timing and effects of these changes, and the above list should not be viewed as guaranteeing a particular outcome. See "1. What is this product?" for a discussion of how the payments you will receive during the life of the product and the payment you may receive at the end of the recommended holding period will be calculated.

In severely adverse market conditions, if you hold the product to the end of the recommended holding period, you may lose your entire investment.

If you sell the product in severely adverse market conditions prior to the recommended holding period, your return may be lower than what you would have received if you held the product to the end of the recommended holding period and may be as low as zero. See "5. How long should I hold it and can I take money out early" below for additional information.

3. What happens if Morgan Stanley B.V. is unable to pay out?

You are exposed to the risk that the issuer or guarantor might be unable to meet its obligations in connection with the product for instance in the event of bankruptcy or an official directive for resolution action. This may materially adversely affect the value of the product and could lead to you losing some or all of your investment in the product. The product is not covered by any deposit protection scheme.

4. What are the costs?

The Reduction in Yield (RIY) shows what impact the total costs you pay will have on the investment return you might get. The total costs take into account one-off, ongoing and incidental costs.

The amounts shown here are the cumulative costs of the product itself, for three different holding periods. They include potential early exit penalties. The figures assume you invest GBP 10,000. The figures are estimates and may change in the future.

Costs over time

Investment: GBP 10,000			
Scenarios	If you cash in after 1 year	If you cash in after 3 years	If you cash in at the end of the recommended holding period
Total costs	GBP 397.62	GBP 397.62	GBP 347.62
Impact on return (RIY) per year	4.46%	1.41%	0.62%

The costs shown in the table above represent how much the expected costs of the product would affect your return, assuming the product performs in line with the moderate performance scenario.

The person selling you or advising you about this product may charge you other costs. If so, this person will provide you with information about these costs, and show you the impact that all costs will have on your investment over time.

Composition of costs

The table below shows:

- The impact each year of the different types of costs on the investment return you might get at the end of the recommended holding period.
- The meaning of the different cost categories.

The table shows the impact on return per year.

The table shows the impact on return per year.			
One-off costs	Entry costs	0.62%	The impact of the costs already included in the price.
	Exit costs	0.00%	The impact of the costs of exiting your investment when it matures.
Ongoing costs	Other ongoing costs	0.00%	The impact of the costs that we take each year for managing your investments.

The costs shown in the table above represent the split of the reduction in yield shown in the costs over time table at the end of the recommended holding period. The split of the actual estimated costs of the product as a percentage of the **product notional amount** is estimated to be as follows: entry costs: 3.47615% and exit costs: 0.00%.

5. How long should I hold it and can I take money out early?

Recommended holding period: 6 years

The product aims to provide you with the return described under "1. What is this product?" above. However, this only applies if the product is held to maturity. It is therefore recommended that the product is held until 12 March 2032 (maturity).

The product does not guarantee the possibility to disinvest other than by selling the product either (1) through the exchange (if the product is exchange traded) or (2) off-exchange, where an offer for such product exists. Save as otherwise disclosed in exit costs (see section "4. What are the costs?" above), no fees or penalties will be charged by the issuer for any such transaction, however an execution fee might be chargeable by your broker if applicable. By selling the product before its maturity, you may receive back less than you would have received if you had kept the product until maturity.

Exchange listing	Luxembourg Stock Exchange (Euro MTF)	Price quotation	Percentage
Smallest tradable unit	GBP 1,000.00		

In volatile or unusual market conditions, or in the event of technical faults/disruptions, the purchase and/or sale of the product can be temporarily hindered and/or suspended and may not be possible at all.

6. How can I complain?

Any complaint regarding the conduct of the person advising on, or selling, the product can be submitted directly to that person.

Any complaint regarding the product or the conduct of the manufacturer of this product can be submitted in writing at the following address: Morgan Stanley & Co. International plc, Structured Products Floor 01, 20 Bank Street, Canary Wharf, London, E14 4AD, by email to: rspcomplaints@morganstanley.com. Please see also <https://sp.morganstanley.com/EU/>. Complaints should include the name of the product, ISIN and reason for the complaint.

7. Other relevant information

The information contained in this Key Information Document does not constitute a recommendation to buy or sell the product and is no substitute for individual consultation with your bank or advisor.

The product is not in any way sponsored, sold or promoted by any relevant stock market, relevant index, related exchange or index sponsor. Further information in respect of the index is available from the index administrator.

The offering of this product has not been registered under the U.S. Securities Act of 1933. This product may not be offered or sold, directly or indirectly, in the United States of America or to U.S. persons. The term "U.S. person" is defined in Regulation S under the U.S. Securities Act of 1933, as amended.

Any additional documentation in relation to the product, in particular, the issuance programme documentation, any supplements thereto and the product terms are published on <https://sp.morganstanley.com/EU/>, all in accordance with relevant legal requirements. These documents are also available free of charge from Morgan Stanley & Co. International plc, Structured Products Floor 01, 20 Bank Street, Canary Wharf, London, E14 4AD.